Highlights Humacyte, Inc.

Equities

HUMA

US44486Q1031

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
4.8 ^USD	+2.13%		-7.16%	+69.01%

06-25	Humacyte, Inc. Presents Positive Preclinical Data for Its Biovascular Pancreas (Bvp??) Program	CI
06-24	Humacyte, Inc.(NasdaqGS:HUMA) added to S&P Biotechnology Select Industry Index	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Humacyte, Inc. Presents Positive Preclinical Data for Its Biovascular Pancreas (Bvp??) Program	06-25	CI
Humacyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Humacyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
Humacyte, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-22	CI
North American Morning Briefing : Stocks Struggle After New Records	03-22	DJ
Humacyte Shares Rise After FDA Grants Priority Review to Vascular Trauma Treatment	02-09	DJ
Humacyte Shares Rise as Application for Potential Vascular Trauma Treatment Gets Priority Review from FDA	02-09	MT
Humacyte Gets Speedy FDA Review of Bioengineered Tissue in Vascular Trauma	02-09	DJ
Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application	02-09	CI
Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel for the Treatment of Vascular Trauma	12-12	CI
Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel?? (HAV??) in the Treatment of Vascular Trauma	11-17	CI
Humacyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel?? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model	16/10/23	CI
Humacyte, Inc. Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel?? (HAV??) in Treatment of Patients with Vascular Trauma	12/09/23	CI
Humacyte, Inc. Announces the Presentation of Results from FDA Regulated, Investigator-Sponsored Clinical Study Conducted At the Mayo Clinic	11/09/23	CI
Humacyte, Inc. Presents Clinical Performance of Human Acellular Vessel from Ukrainian Humanitarian Program	15/08/23	CI
Humacyte, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Humacyte, Inc. Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel	03/08/23	CI
Humacyte, Inc. Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel(Tm) (Hav(Tm)) for Vascular Trauma Repair	26/07/23	CI
Humacyte's Q1 Net Loss Widens; Signs Funding Agreement of Up to $160 Million With Oberland Capital Management	12/05/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Humacyte, Inc.

Equities

HUMA

US44486Q1031

Highlights

Filters